APLT - Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

2024-05-28 10:23:38 ET

Summary

• Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors.
• Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion.
• AT-001’s efficacy in diabetic cardiomyopathy is inconclusive; significant results are only in certain subgroups.
• Hold APLT stock due to high risks despite potential in niche markets; it's suitable for a diversified high-risk portfolio segment.

Govorestat’s Race Against Galactose: A Sweet or Sour Future?

Applied Therapeutics ( APLT ) is a clinical-stage biotech company developing govorestat for galactosemia, SORD deficiency, PMM2-CDG, and AT-001 for diabetic cardiomyopathy....

For further details see: